INCYIncyte
$119.69+29% 1Y
$119.69
$90.3052 weeks$129.88
The financials
Incyte by the numbers
Incyte (INCY) reported revenue of $1.56B in Q3 2026 (quarter ended Sep 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 93% and net loss of $785M. For the full year FY2025, revenue was $5.14B (+21% year on year) and net income $1.29B. Its largest product in Q2 2026 (quarter ended Jun 30, 2026) was JAKAFI at $817M, 48% of the disclosed total, well ahead of OPZELURA at 26%. The next results filing is expected around Feb 9, 2027, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $1.56B | $1.37B | +14% |
| Gross profit | $1.45B | $1.27B | +14% |
| Operating income | −$708M | $444M | to a loss |
| Net income | −$785M | $424M | to a loss |
| Diluted EPS | −$3.86 | $2.11 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| JAKAFI | $817M | 48% |
| OPZELURA | $450M | 26% |
| JAKAVI Royalty | $124M | 7.2% |
| NIKTIMVO | $60M | 3.5% |
| MINJUVIMONJUVI | $54M | 3.1% |
| ZYNYZ | $50M | 2.9% |
| OLUMIANT | $39M | 2.2% |
| OLUMIANT Royalty | $38M | 2.2% |
| ICLUSIG | $34M | 2.0% |
| PEMAZYRE | $23M | 1.4% |
| Milestone And Contract | $11M | 0.7% |
| TABRECTA | $6.7M | 0.4% |
| TABRECTA Royalty | $6.7M | 0.4% |
| Other Product Royalty | $5.3M | 0.3% |
Over its last three fiscal years Incyte booked income tax of 31.9% of its pretax profit, above the 21.3% median for US companies in our tax study.
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.72B (+31%)
ZYNYZ grew +460% year on yearTABRECTA Royalty +0.89% year on year
What Jun 2026 was made of
JAKAFI48%OPZELURA26%JAKAVI Royalty7%NIKTIMVO4%MINJUVIMONJUVI3%ZYNYZ3%OLUMIANT2%OLUMIANT Royalty2%ICLUSIG2%PEMAZYRE1%Milestone And Contract1%TABRECTA0%TABRECTA Royalty0%Other Product Royalty0%
Segment Latestvs last quartervs a year ago
- JAKAFI$816.7M$816.7Mvs last quarter +7.8%vs a year ago +6.9%+7.8%+6.9%
- OPZELURA$449.7M$449.7Mvs last quarter +214%vs a year ago +173%+214%+173%
- JAKAVI Royalty$124.2M$124.2Mvs last quarter +18%vs a year ago +13%+18%+13%
- NIKTIMVO$60.3M$60.3Mvs last quarter +9.5%vs a year ago +67%+9.5%+67%
- MINJUVIMONJUVI$53.7M$53.7Mvs last quarter +9.1%vs a year ago +72%+9.1%+72%
- ZYNYZ$49.9M$49.9Mvs last quarter +21%vs a year ago +460%+21%+460%
- OLUMIANT$38.5M$38.5Mvs last quarter +5.8%vs a year ago +15%+5.8%+15%
- OLUMIANT Royalty$38.5M$38.5Mvs last quarter +5.7%vs a year ago +15%+5.7%+15%
- ICLUSIG$34.4M$34.4Mvs last quarter -3.0%vs a year ago +5.1%-3.0%+5.1%
- PEMAZYRE$23.4M$23.4Mvs last quarter +3.9%vs a year ago +5.5%+3.9%+5.5%
- Milestone And Contract$11.2M$11.2Mvs last quarter -34%vs a year ago +124%-34%+124%
- TABRECTA$6.7M$6.7Mvs last quarter +12%vs a year ago +1.5%+12%+1.5%
- TABRECTA Royalty$6.7M$6.7Mvs last quarter +12%vs a year ago +0.89%+12%+0.89%
- Other Product Royalty$5.3M$5.3Mvs last quarter +64%vs a year ago +314%+64%+314%
Biotechnology
The closest names by size in the same industry